keyword
MENU ▼
Read by QxMD icon Read
search

Intravitreal injection

keyword
https://www.readbyqxmd.com/read/28432581/comparison-of-immediate-versus-deferred-intravitreal-bevacizumab-in-macular-oedema-due-to-branch-retinal-vein-occlusion-a-pilot-study
#1
M A Khan, Varakutti Mallika, Dattakiran Joshi
PURPOSE: To compare visual and anatomical recovery of immediate versus deferred intravitreal Bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion (BRVO). METHODS: In a pilot study, 40 treatment naïve patients of branch retinal vein occlusion with macular oedema and vision 6/12 or less presenting within one month of onset were randomised into 2 groups (20 each) to receive either immediate intravitreal Bevacizumab or deferred (after 3 months of observation)...
April 21, 2017: International Ophthalmology
https://www.readbyqxmd.com/read/28432109/early-response-to-ranibizumab-predictive-of-functional-outcome-after-dexamethasone-for-unresponsive-diabetic-macular-oedema
#2
Maria Vittoria Cicinelli, Michele Cavalleri, Lea Querques, Alessandro Rabiolo, Francesco Bandello, Giuseppe Querques
PURPOSE: To analyse the effects of intravitreal dexamethasone implant in patients suffering from diabetic macular oedema (DME) on the basis of their visual and functional response to antivascular endothelial growth factor (VEGF) loading dose, in order to early shift to corticosteroids in poorly responding patients. DESIGN: Retrospective monocentric study. METHODS: Data of patients with diabetes shifted to 0.7 mg dexamethasone implant after three injections of ranibizumab (RNB) and followed-up to 12 months were reviewed...
April 21, 2017: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/28430326/in-vivo-intraocular-pressure-monitoring-during-microincision-vitrectomy-with-and-without-active-control-of-infusion-pressure
#3
Hyun S Yang, Young I Yun, Jong H Park, Sangkyung Choi, Je M Woo
PURPOSE: To evaluate intraocular pressure (IOP) fluctuation during vitrectomy, we directly monitored IOP in vivo using 2 vitrectomy machines with or without constant infusion pressure monitoring and control. METHODS: Among 61 eyes of 61 consecutive patients, 32 were assigned to the Accurus system (group 1) and 29 were assigned to the Constellation system (group 2) in this prospective case series. The IOP fluctuations were evaluated during routine vitrectomy procedures...
April 4, 2017: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/28428895/suppression-of-retinal-neovascularization-by-inhibition-of-galectin-1-in-a-murine-model-of-oxygen-induced-retinopathy
#4
Ning Yang, Wenxi Zhang, Tao He, Yiqiao Xing
Galectin-1 (Gal-1) has been proved to be an important factor in the process of tumor angiogenesis recently. As a small molecule, OTX008 serves as a selective inhibitor of Gal-1. In this study, the role of Gal-1 and the antiangiogenic effect of OTX008 on retinal neovascularization (RNV) were investigated using a mouse model of oxygen-induced retinopathy. The outcome indicated that Gal-1 was overexpressed and closely related to retinal neovessels in OIR. After intravitreal injection of OTX008 at P12, the RNV was significantly reduced at P17, measuring by cross-sectional H&E staining and whole-mount fluorescence...
2017: Journal of Ophthalmology
https://www.readbyqxmd.com/read/28427072/anti-vascular-endothelial-growth-factor-injections-the-new-standard-of-care-in-proliferative-diabetic-retinopathy
#5
Xintong Li, Marco A Zarbin, Neelakshi Bhagat
For decades, panretinal photocoagulation (PRP) has been the standard of care for the treatment of proliferative diabetic retinopathy (PDR). The relatively recent advent of anti-vascular endothelial growth factor (VEGF) formulations for intravitreal injection has provided a fresh perspective on PDR treatment, especially in eyes with concurrent diabetic macular edema (DME). The anti-VEGF agent ranibizumab has demonstrated a potentially protective effect on eyes with DME in terms of progression to PDR in the RIDE/RISE trials, as has aflibercept in the VIVID/VISTA trials...
2017: Developments in Ophthalmology
https://www.readbyqxmd.com/read/28427070/practical-lessons-from-protocol-t-for-the-management-of-diabetic-macular-edema
#6
Lekha Mukkamala, Neelakshi Bhagat, Marco Zarbin
PURPOSE: To review the results of Diabetic Retinopathy Clinical Research Network Protocol T, as applied to clinical practice. METHODS: Review of major publications reporting the results of Protocol T, a randomized single-masked (in year-1 only), multicenter clinical trial comparing aflibercept, bevacizumab, and ranibizumab as treatment option for center-involving diabetic macular edema (DME). The main outcome measures were change in visual acuity (VA), central subfield thickness (CST) on optical coherence tomography, cost effectiveness, burden of care, and safety...
2017: Developments in Ophthalmology
https://www.readbyqxmd.com/read/28427069/practical-lessons-from-protocol-i-for-the-management-of-diabetic-macular-edema
#7
Lekha Mukkamala, Neelakshi Bhagat, Marco A Zarbin
Protocol I, a multicenter randomized clinical trial, compared the visual outcomes of patients treated with 0.5 mg intravitreal ranibizumab with either prompt or deferred (by 24 weeks laser), 4 mg intravitreal triamcinolone with prompt laser, or sham injection with prompt laser for the treatment of center-involving diabetic macular edema (DME). A total of 854 adult patients with type I or II diabetes and any level of non-proliferative diabetic retinopathy or proliferative retinopathy with adequate panretinal photocoagulation, with best-corrected visual acuity (BCVA) of 78 to 24 ETDRS letters (Snellen equivalent of 20/32 to 20/320) and visual loss attributed to macular edema, or retinal thickening with central subfield thickness of at least 250 µm by OCT were enrolled...
2017: Developments in Ophthalmology
https://www.readbyqxmd.com/read/28427068/intravitreal-steroids-in-diabetic-macular-edema
#8
Rosangela Lattanzio, Maria Vittoria Cicinelli, Francesco Bandello
Over the past decade, great strides have been made in the management of diabetic macular edema (DME). Therapeutic alternatives now include focal/grid laser photocoagulation, vitreo-retinal surgery, and intraocular injection of anti-angiogenic and steroid molecules. Intravitreal administration of steroids represents a fundamental alternative for recalcitrant and naive eyes with DME, especially in those cases when anti-vascular endothelial growth factor (VEGF) agents are contraindicated or a treatment regimen with fewer intravitreal injections is required...
2017: Developments in Ophthalmology
https://www.readbyqxmd.com/read/28427066/intravitreal-ranibizumab-in-diabetic-macular-edema-long-term-outcomes
#9
Ilaria Zucchiatti, Francesco Bandello
Intravitreal ranibizumab (RBZ) has been shown in multiple randomized clinical trials to be a valuable treatment for diabetic macular edema (DME), promoting a significant improvement in best-corrected visual acuity (BCVA) and in anatomic outcomes. Compared to sham (RISE and RIDE studies), RBZ rapidly and sustainably improved BCVA and decreased macular edema at 2 years, reducing the risk of further vision loss, with low rates of local or systemic side effects. Compared to macular laser photocoagulation (READ-2 study), RBZ provided a greater improvement in BCVA and regression in foveal thickness, but required a higher number of injections compared to patients treated with both RBZ and laser...
2017: Developments in Ophthalmology
https://www.readbyqxmd.com/read/28426623/intravitreal-dexamethasone-implantation-in-patients-with-different-morphological-diabetic-macular-edema-having-insufficient-response-to-ranibizumab
#10
Havva Kaldırım, Serpil Yazgan, Kursat Atalay, Ceren Gurez, Fatma Savur
PURPOSE: To evaluate the effectiveness of a single intravitreal injection of dexamethasone implant in resistant diabetic macular edema that have different morphological types. METHODS: In this retrospective study, 31 patients (35 eyes) with persistent diabetic macular edema, who underwent a single injection of dexamethasone implant, were evaluated. Diabetic macular edema was classified into three types: diffuse retinal thickening (n = 10), cystoid macular edema (n = 13), and serous retinal detachment (n = 12)...
April 19, 2017: Retina
https://www.readbyqxmd.com/read/28426622/changes-in-central-choroidal-thickness-after-treatment-of-diabetic-macular-edema-with-intravitreal-bevacizumab-correlation-with-central-macular-thickness-and-best-corrected-visual-acuity
#11
Ramin Nourinia, Hamid Ahmadieh, Elnaz Nekoei, Parviz Malekifar, Zahra Tofighi
PURPOSE: To assess the effect of intravitreal injection of bevacizumab on central choroidal thickness (CCT) and its relationship with central macular thickness (CMT) and best-corrected visual acuity (BCVA) changes in eyes with center-involving diabetic macular edema. METHODS: This prospective interventional case series included 20 eyes of 20 patients with center-involving diabetic macular edema naive to treatment. The BCVA assessment, complete eye examination, enhanced depth optical coherence tomography, and fluorescein angiography were performed at baseline followed by 3 monthly intravitreal injection of bevacizumab...
April 19, 2017: Retina
https://www.readbyqxmd.com/read/28425224/nanocarrier-mediated-retinal-drug-delivery-overcoming-ocular-barriers-to-treat-posterior-eye-diseases
#12
REVIEW
Rohit Bisht, Abhirup Mandal, Jagdish K Jaiswal, Ilva D Rupenthal
Effective drug delivery to the retina still remains a challenge due to ocular elimination mechanisms and complex barriers that selectively limit the entry of drugs into the eye. To overcome these barriers, frequent intravitreal injections are currently used to achieve high drug concentrations in vitreous and retina. However, these repetitive injections may result in several side effects. Recent advancements in the field of nanoparticle-based drug delivery could overcome some of these unmet needs and various preclinical studies conducted to date have demonstrated promising results of nanotherapies in the treatment of retinal diseases...
April 20, 2017: Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology
https://www.readbyqxmd.com/read/28424992/intravitreal-anti-vegf-treatment-for-choroidal-neovascularization-secondary-to-punctate-inner-choroidopathy
#13
T Barth, F Zeman, H Helbig, M-A Gamulescu
PURPOSE: To assess the outcome of patients with choroidal neovascularization (CNV) secondary to punctate inner choroidopathy (PIC) receiving intravitreal anti-VEGF (vascular endothelial growth factor) injections. METHODS: Sixteen eyes of 16 patients diagnosed with CNV secondary to PIC were retrospectively assessed. RESULTS: Eleven women and five men with a mean age of 35 years (SD 11, range 16-56 years) received intravitreal anti-VEGF for PIC-related CNV...
April 19, 2017: International Ophthalmology
https://www.readbyqxmd.com/read/28424619/retinal-and-circulating-mirnas-in-age-related-macular-degeneration-an-in-vivo-animal-and-human-study
#14
Giovanni L Romano, Chiara B M Platania, Filippo Drago, Salvatore Salomone, Marco Ragusa, Cristina Barbagallo, Cinzia Di Pietro, Michele Purrello, Michele Reibaldi, Teresio Avitabile, Antonio Longo, Claudio Bucolo
Age related macular degeneration (AMD) is the leading cause of blindness among people aged 50 and over. Retinal deposition of amyloid-β (Aβ) aggregates in AMD patients has suggested a potential link between AMD and Alzheimer's disease (AD). We have evaluated the differential retinal expression profile of miRNAs in a rat model of AMD elicited by Aβ. A serum profile of miRNAs in AMD patients has been also assessed using single TaqMan assay. Analysis of retina from rats intravitreally injected with Aβ revealed that miR-27a, miR-146a, and miR-155 were up-regulated in comparison to control rats...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28422835/predictive-factors-of-better-outcomes-by-monotherapy-of-an-antivascular-endothelial-growth-factor-drug-ranibizumab-for-diabetic-macular-edema-in-clinical-practice
#15
Shinri Sato, Hajime Shinoda, Norihiro Nagai, Misa Suzuki, Atsuro Uchida, Toshihide Kurihara, Mamoru Kamoshita, Yohei Tomita, Chigusa Iyama, Sakiko Minami, Kenya Yuki, Kazuo Tsubota, Yoko Ozawa
Intravitreal ranibizumab (IVR) has been approved for treating diabetic macular edema (DME), and is used in daily clinical practice. However, the treatment efficacies of IVR monotherapy in real-world clinical settings are not well known.The medical records of 56 eyes from 38 patients who received their first IVR for DME between April 2014 and March 2015, and were retreated with IVR monotherapy as needed with no rescue treatment, such as laser photocoagulation, were retrospectively reviewed. The clinical course, best-corrected visual acuity (BCVA), and fundus findings at baseline, before the initial IVR injection, and at 12 months, were evaluated...
April 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28422832/two-year-result-of-intravitreal-bevacizumab-for-diabetic-macular-edema-using-treat-and-extend-protocol
#16
Masahiko Sugimoto, Atsushi Ichio, Takayasu Nunome, Mineo Kondo
To determine the efficacy of the treat and extend (TAE) protocol with intravitreal bevacizumab (IVB) for managing diabetic macular edema (DME).Retrospective, single-center study.For this retrospective study, 42 eyes of 42 patients were initially treated with 3 consecutive monthly IVB injections (loading phase), after which they were selected for different additional therapies. For the TAE protocol, the baseline treatment interval was selected to be 8 weeks and was sequentially lengthened by 2 weeks if the central macular thickness (CMT) was <300 μm at 2 consecutive examinations...
April 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28421399/effect-of-intravitreal-aflibercept-eylea-%C3%A2-on-retrobulbar-hemodynamics-in-patients-with-neovascular-age-related-macular-degeneration
#17
Mustafa Gok, Hasan Burhanettin Kapti
PURPOSE: To investigate the short-term effect of single intravitreal aflibercept injection on retrobulbar blood flow in patients with neovascular age-related macular degeneration (nAMD). METHODS: Twenty eyes of 20 patients with nAMD scheduled for single intravitreal aflibercept (Eylea(®)) injection and 20 fellow eyes (uninjected) were enrolled in this prospective interventional study. The hemodynamic parameters of the ophthalmic artery (OA), central retinal artery (CRA) and posterior ciliary artery (PCA) comprising peak systolic velocity (PSV), end-diastolic velocity (EDV), and resistive index (RI) were measured by using color Doppler ultrasonography (CDU) in both injected and uninjected fellow eyes at baseline and 1 week after the injection...
April 18, 2017: International Ophthalmology
https://www.readbyqxmd.com/read/28420956/retinal-gene-therapy-surgical-vector-delivery-in-the-translation-to-clinical-trials
#18
REVIEW
G Alex Ochakovski, K Ulrich Bartz-Schmidt, M Dominik Fischer
An exceptionally high number of monogenic disorders lead to incurable blindness, making them targets for the development of gene-therapy. In order to successfully apply therapeutic vector systems in vivo, the heterogeneity of the disease phenotype needs to be considered. This necessitates tailored approaches such as subretinal or intravitreal injections with the aim to maximize transduction of target cell populations, while minimizing off-target effects and surgical complications. Strategic decisions on parameters of the application are crucial to obtain the best treatment outcomes and patient safety...
2017: Frontiers in Neuroscience
https://www.readbyqxmd.com/read/28419398/pre-existing-rpe-atrophy-and-defects-in-the-external-limiting-membrane-predict-early-poor-visual-response-to-ranibizumab-in-neovascular-age-related-macular-degeneration
#19
Souska Zandi, Florian Weisskopf, Justus G Garweg, Isabel B Pfister, Christian Pruente, Florian Sutter, Katja Hatz
BACKGROUND AND OBJECTIVES: The aim of this study was to identify the rate of early visual acuity poor responders in patients with neovascular age-related macular degeneration (AMD) after the first intravitreal injection of ranibizumab (Lucentis; Genentech, South San Francisco, CA) and to determine potential predictors for early response. PATIENTS AND METHODS: Patients with choroidal neovascularization secondary to AMD were evaluated before and 1 month after their first ranibizumab treatment...
April 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28419394/use-of-corticosteroids-in-the-treatment-of-patients-with-diabetic-macular-edema-who-have-a-suboptimal-response-to-anti-vegf-recommendations-of-an-expert-panel
#20
Carl D Regillo, David G Callanan, Diana V Do, Howard F Fine, Nancy M Holekamp, Baruch D Kuppermann, Michael A Singer, Rishi P Singh
BACKGROUND AND OBJECTIVE: Guidance on the use of corticosteroids in the treatment of diabetic macular edema (DME) is lacking. This study aimed to develop a clinically recommended treatment paradigm for DME with emphasis on the role of corticosteroids. PATIENTS AND METHODS: An expert panel of nine retinal specialists in the United States developed consensus recommendations for DME treatment through a modified Delphi process. RESULTS: The panelists typically use intravitreal injections of vascular endothelial growth factor (VEGF) antagonists as first-line treatment of DME and switch patients with an inadequate response to anti-VEGF therapy (failure of best-corrected visual acuity to improve to 20/40 or better because of edema after three to six monthly injections, or a less-than-50% reduction in excess macular thickness after three to four monthly injections) to intravitreal corticosteroid treatment...
April 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
keyword
keyword
69928
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"